How should hyperkalaemia with a serum potassium of 5.6 mEq/L be corrected?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of Hyperkalemia at 5.6 mEq/L

Yes, you should treat hyperkalemia of 5.6 mEq/L, as this falls into the moderate range (5.5-6.0 mEq/L) and warrants intervention to prevent adverse outcomes and enable continuation of life-saving medications. 1, 2

Classification and Clinical Context

A potassium level of 5.6 mEq/L is classified as moderate hyperkalemia according to current guidelines 1. While 5.5 mEq/L is widely accepted as the threshold for hyperkalemia 2, the decision to treat should focus on clinical impact rather than rigid thresholds alone 2.

Critical First Steps

Before treating, rule out pseudohyperkalemia:

  • Repeat the measurement if hemolysis, poor phlebotomy technique, or fist clenching during blood draw occurred 2
  • Plasma potassium runs 0.1-0.4 mEq/L lower than serum due to platelet release during coagulation 2

Obtain an ECG immediately - though only 44% of patients with hyperkalemia receive one in practice 3, and notably, 50% of patients with K+ ≥6.5 mEq/L show no ECG changes 3. Absent ECG changes do NOT exclude the need for treatment 4.

Treatment Algorithm for K+ 5.6 mEq/L

Step 1: Identify and Remove Reversible Factors 5

Review medications immediately:

  • NSAIDs (most commonly implicated) 3
  • Potassium-sparing diuretics (spironolactone, amiloride, triamterene)
  • Trimethoprim-sulfamethoxazole 3
  • Beta-blockers
  • Potassium supplements or salt substitutes 1

Assess for:

  • Volume depletion (can worsen hyperkalemia with RAASi) 6
  • Metabolic acidosis (correct with sodium bicarbonate if present) 2
  • Constipation 5
  • Acute kidney injury

Step 2: Do NOT Discontinue RAASi Therapy

This is critical: Discontinuing RAASi therapy is associated with higher mortality and major adverse cardiovascular events 2. According to ACC/AHA/HFSA guidelines, RAASi is not usually stopped for mild-to-moderate hyperkalemia (5.0-5.9 mEq/L) 2.

The European Society of Cardiology recommends for K+ 5.0-6.5 mEq/L: initiate potassium-lowering therapy while maintaining maximum-tolerated RAASi dose 2.

Step 3: Initiate Potassium-Lowering Treatment

For non-acute moderate hyperkalemia (5.6 mEq/L without ECG changes):

First-line approach:

  • Loop diuretics (furosemide) if patient has residual kidney function and is hypervolemic 2
  • Correct metabolic acidosis with sodium bicarbonate if present 2

Second-line - Potassium Binders:

The newer potassium binders are preferred over sodium polystyrene sulfonate (SPS):

  • Sodium zirconium cyclosilicate (SZC/Lokelma) or Patiromer (Veltassa) 2, 5

    • Both have documented efficacy in clinical trials
    • More palatable than SPS, improving adherence 2
    • Can maintain normokalemia for at least one year 5
    • Enable RAASi optimization 2
  • Avoid SPS (Kayexalate) when possible due to:

    • Limited clinical data supporting efficacy 2
    • Warning for severe, potentially fatal gastrointestinal adverse events 7

Step 4: Dietary Counseling - A Nuanced Approach

Do NOT prescribe a strict low-potassium diet. The evidence supporting dietary potassium restriction is limited, and such diets are difficult to maintain, especially with concurrent diabetes or sodium restrictions 2.

Instead:

  • Focus on reducing non-plant sources of potassium 5, 8
  • Maintain potassium-rich plant foods for cardiovascular benefits 2
  • This approach is being reassessed in current practice 5, 8

Step 5: Monitoring

Reassess potassium within 1 week after any intervention 2. For patients on RAASi:

  • Check K+ within 7-10 days after starting or increasing RAASi doses 2
  • More frequent monitoring for high-risk patients (CKD, diabetes, HF, history of hyperkalemia) 2

Common Pitfalls to Avoid

  1. Discontinuing RAASi prematurely - This increases mortality risk 2. Only discontinue if K+ >6.5 mEq/L per ESC guidelines 2

  2. Relying solely on ECG - 50% of patients with severe hyperkalemia show no ECG changes 3

  3. Prescribing overly restrictive potassium diets - Conflicts with heart-healthy eating and lacks strong evidence 2, 5

  4. Using SPS as first-line - Newer binders are safer and more effective 2, 7

  5. Not addressing 20% recurrence risk - Patients with non-reversible risk factors need ongoing treatment, not just acute correction 5

Special Considerations

If patient has CKD, HF, or diabetes: These patients commonly have K+ levels up to 6.0 mEq/L without arrhythmias 1. The focus should be on maintaining RAASi therapy while managing potassium, as RAASi discontinuation worsens outcomes in these populations 2.

If K+ rises above 6.5 mEq/L: Consider discontinuing or reducing RAASi temporarily per ESC guidelines, but plan for reinitiation once K+ <5.0 mEq/L 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.